乙型肝炎肝硬化失代偿期抗病毒治疗的研究进展

Research progress in antiviral therapy for decompensated hepatitis B cirrhosis

乙型肝炎肝硬化失代偿期是慢性乙型肝炎、肝纤维化发展的最终结局之一。大量的研究证明抗病毒治疗可以延缓病情进展,明显改善临床结局,减少并发症的发生,延缓失代偿肝硬化进程,最终提高生存期。核苷和核苷酸类药物是目前失代偿期乙型肝炎肝硬化的主要抗病毒药物。介绍了适用于乙型肝炎肝硬化失代偿期的抗病毒药物,针对治疗中的一些问题进行探讨,指出在临床工作中,在规范化抗病毒的前提下应遵循个体化治疗的原则。

Decompensated hepatitis B cirrhosis is one of the final outcomes of chronic hepatitis B and liver fibrosis. Extensive studies have demonstrated that antiviral therapy can slow disease progression,improve clinical outcomes,reduce complications,slow decompensated cirrhosis progression,and improve survival. At present,nucleoside and nucleotide analogues are the most common antiviral agents in the treatment of decompensated hepatitis B cirrhosis. This paper introduces effective antiviral agents against decompensated hepatitis B cirrhosis and discusses potential problems in antiviral treatment,suggesting that personalized medication should be achieved on the basis of standardized antiviral treatment in clinical practice.